A-20. Drugs used for treatment of heart failure II: Cardiac glycosides Flashcards
Cardiac Glycosides
Digoxin
Digitoxin
Strophanthins( e.g. ouabain)
Cardiac Glycosides (MOA)
Bind and inhibit Na/K-ATPase (20-30% ATPases inhibited = therapeutic effect) → ↑ IC Na + → Na/Ca exchange slows (or reverses) → IC Ca ++ ↑ → more Ca in SR → trigger Ca enters through L-type Ca channel
→ AP from trigger Ca ++ initiates higher Ca ++ current from SR → positive inotropy
- (Ca ++ storage ↓ in some HF due to SERCA dysfunction → glycosides restore SERCA function).
- Also stimulate vagus centrally → ACh at cardiac M2 receptors open K + channels →
hyperpolarization → slows sinus and AV nodes → bradycardia.
Cardiac Glycosides (Kinetics)
Digoxin : faster onset, oral, not metabolized, kidney elimination, DOA 36-40 hr, lower protein binding.
Digitoxin : slower onset, oral, metabolized and eliminate by liver , DOA 5-7 days, higher protein binding.
Both drugs have a narrow therapeutic index
Digoxin (Indications)
- CHF - NYHA stages III-IV (when ACE-I / diuretics fail). does not ↓ mortality.
- Atrial flutter and atrial fibrillation - digoxin vagal stimulation ↓ aberrant automaticity.
- Used rarely in supraventricular tachycardia for AV node slowing, (mainly if associated with HF).
Digoxin (Contraindications)
Absolute :
1. Hypertrophic CMP.
2. WPW - digoxin ↑ AV node refractory
period, which may stimulate conduction through the accessory pathway.
3. AV block - vagal effects can exacerbate
heart block.
4. Diastolic HF - ↑ contractility from digoxin can ↓ diastolic relaxation.
Relative :
- Sinus Bradycardia and sick sinus syndrome.
- With other negative chronotropes (verapamil, diltiazem, amiodarone).
- Circumstances with ↑ digitalis sensitivity (hypokalemia, etc).
- Renal failure → use digitoxin instead.
Digoxin Toxicity (Symptoms and Treatment)
- Hyperkalemia - via Na/K-ATPase inhibition.
- Arrhythmias - PVCs are most common, but many other arrhythmias can be seen.
(More than 20-30% ATPases blocked → IC Ca ++ too high → delayed afterdepolarization
(DAD) → slight ↑ in membrane potential after normal cardiac AP → extrasystoles (PVC,
ventricular tachycardia, ventricular fibrillation)). - Vagal stimulation plus excess IC Ca ++ can lead to ventricular bigeminy or AV block.
(Bradycardia can result from vagal
stimulation). - ECG signs characteristic of digoxin toxicity: shortened QT , scooped ST depression and T inversion.
- Vision Issues - color vision disturbances, blurred vision, photosensitivity, xanthopsia (yellow vision).
- Neuro Issues - HA, anxiety, nightmare, hallucinations, lethargy, disorientation.
- GI Issues - via ATPase inhibition in GI tract: nausea, vomiting, abdominal pain.
Treatment :
- Atropine for vagal stimulation symptoms.
- Lidocaine/phenytoin (type I/B antiarrhythmics) for ventricular tachycardias.
- Digiban - digitalis binding Ab (used for mainly suicide attempts related to psychiatric
symptoms) .
factors / substances that increase digoxin toxicity and drug interactions (6).
- Hypokalemia - mostly with K-wasting diuretics, sometimes via diarrhea/vomiting; glycosides bind competitively to ATPase’s K + binding site, so less K + → ↑ digitalis binding.
* Always monitor K levels when diuretic and glycoside used together.
* ACE-I, ARB and K-sparing diuretics can also → hyperkalemia → ↓ digitalis binding / effect. - Hypercalcemia - can increase risk of DAD → ES / Vtach.
- Hypomagnesemia - Mg needed for ATPase function → ↓ Mg with digoxin → increased digoxin effect (ex: loop diuretics waste Mg).
- Renal Damage - ↑ half-life of digoxin, due to its renal elimination. always monitor BUN/creatinine in renal patients on digoxin. often must switch to digitoxin instead due to hepatic elimination.
* Amiodarone, verapamil, diltiazem and
quinidine all compete with digoxin for renal elimination. - Beta Blockers - digoxin should be used cautiously with BBs due to combined inhibitory effects of both drugs on SA/AV nodes.
- Antibiotics - digoxin is inactivated in GI tract by flora → abx ↑ serum levels.